Macrogenics (MGNX) Income from Discontinued Operations (2025 - 2026)
Powered by 
Analysis
Macrogenics (MGNX) Income from Discontinued Operations (2025 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.72 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.56 Bn | 58.38 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.87 Bn | 52.73 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 40.08 Bn | 34.98 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.20 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.54 Bn | 27.70 Bn | - | - |
| 9 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | - |
| 10 | Macrogenics | 274.73 Mn | 160.82 Mn | - | 89.16 Mn |